

#19

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla
Attorney Docket Number	20553D-000611US

RECEIVED
JUN 02 2003
TECH CENTER 1600/2900**U.S. PATENT DOCUMENTS**

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RPS	AA	US-6,303,573 B1	10/16/2001	Ruoslathi et al.	_____

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
RPS	AB	EP	0 721 983	A1	07/17/1996	ZymoGenetics, Inc.	_____	<input type="checkbox"/>
RPS	AC	WO	96/26736	A1	09/06/1996	Ludwig Institute for Cancer Research and Helsinki University Licensing Ltd.	_____	<input type="checkbox"/>
	AD	WO	97/10507	A1	03/20/1997	La Jolla Cancer Research Foundation	_____	<input type="checkbox"/>
	AE	WO	97/12519	A1	04/10/1997	St. Elizabeth's Medical Center of Boston, Inc.	_____	<input type="checkbox"/>
RPS							_____	<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RPS	AF	Arora et al., 1999, "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells," <i>Cancer Research</i> 59:18-188	
	AG	Banai et al., 1994, "Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs," <i>Circulation</i> 89(5):2183-2189	
	AH	Billups et al., 1995, "Expression of E-selectin mRNA during ischemia/reperfusion injury," <i>J. Lab. Clin. Med.</i> 125:626-633	
	AI	Bowles et al., 1997, "Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium," <i>Cardiovascular Research</i> 35:422-430	
RPS	AJ	Deckert et al., 1998, "The complete genome of the hyperthermophilic bacterium <i>Aquifex aeolicus</i> ," <i>Nature</i> 392:353-358	

Examiner
Signature

RPS

Date

Considered


9/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9058197 v1



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla
Attorney Docket Number	20553D-000611US

RECEIVED
JUN 02 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RM	AK	Indolfi and Chiariello, 1998, "Gene therapy for cardiovascular disorders," <i>Cardiologia</i> 43(4):365-373	
	AL	Isner <i>et al.</i> , 1996, "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF ₁₆₅ in patient with ischaemic limb," <i>Lancet</i> 348:370-374	
	AM	Knight and Fox, 1995, "The vicious circle of ischemic left ventricular dysfunction," <i>Am. J. Cardiol.</i> 75:10E-15E	
	AN	Korthuis <i>et al.</i> , 1994, "Role of neutrophil-endothelial cell adhesion in inflammatory disorders," <i>Journal of Critical Care</i> 9(1):47-71	
	AO	Kukielka <i>et al.</i> , 1995, "Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium," <i>Molecular and Cellular Biochemistry</i> 147:5-12	
	AP	Lefer and Lefer, 1993, "Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock," <i>Annu. Rev. Pharmacol. Toxicol.</i> 33:71-90	
	AQ	Losordo <i>et al.</i> , 1998, "Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF ₁₆₅ as sole therapy for myocardial ischemia," <i>Circulation</i> 98:2800-2804	
	AR	Ma <i>et al.</i> , 1992, "Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion,"	
	AS	Marche <i>et al.</i> , 1997, "Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy," <i>International Journal of Cardiology</i> 62(Suppl. 2):S17-S22	
	AT	Meredith <i>et al.</i> , 1993, "Role of endothelium in ischemic coronary syndromes," <i>Am. J. Cardiol.</i> 72:27C-32C	
	AU	Rader, D. J., 1997, "Gene therapy for atherosclerosis," <i>Int. J. Clin. Lab. Res.</i> 27:35-43	
	AV	Scalia <i>et al.</i> , 1996, "Myocardial protection by N,N,N-trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin," <i>Journal of Leukocyte Biology</i> 59:317-324	
	AW	Schachter, M., 1997, "Calcium antagonists and atherosclerosis," <i>International Journal of Cardiology</i> 62(Suppl. 2):S9-S15	
RM	AX	Schachter, M., 1997, "Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers," <i>International Journal of Cardiology</i> 62(Suppl. 2):S85-S90	

Examiner
Signature

RM

Date
Considered

9/15/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 1

Complete if Known

Application Number	09/782,650
Filing Date	February 12, 2001
First Named Inventor	Arnold J. Levine
Art Unit	1632
Examiner Name	Ram R. Shukla
Attorney Docket Number	20553D-000611US

RECEIVED
JUN 8 2 2003
TECH CENTER 1800/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RRS	AY	Secombe and Schaff, 1995, "Coronary artery endothelial function after myocardial ischemia and reperfusion," <i>Ann. Thorac. Surg.</i> 60:778-788	
	AZ	Simari and Nabel, 1996, "Genetic therapy," <i>Semin. Intervent. Cardiol.</i> 1:77-83	
	BA	Somanchi <i>et al.</i> , 1998, " <i>Chlamydomonas reinhardtii</i> cDNAs upregulated in low-CO ₂ conditions: expression and analyses," <i>Can. J. Bot.</i> 76:1003-1009	
	BB	Trost <i>et al.</i> , 1998, "Protection against myocardial dysfunction after a brief ischemic period in transgenic mice expressing inducible heat shock protein 70," <i>J. Clin. Invest.</i> 101:855-862	
	BC	Weyrich <i>et al.</i> , 1995, "Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium," <i>J. Leukoc. Biol.</i> 57:45-55	
RRS	BD	Youker <i>et al.</i> , 1994, "Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart," <i>Circulation</i> 89:2736-2746	

Examiner Signature	RRS	Date Considered	9/15/03
-----------------------	-----	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.